Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant PharmovaBOM:530019 -2.75%70 Days Inventory is 157.54 as of Mar. 2026, which is 21% below its 10-year median of 198.79. GuruFocus rates BOM:530019 with a GF Score™ of 70/100 and a GF Value™ of ₹1,069.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Jubilant Pharmova ranks worse than 50.16% on this metric.
The historical rank and industry rank for Jubilant Pharmova's Days Inventory or its related term are showing as below:
BOM:530019'
s Days Inventory Range Over the Past 10 Years
Min: 134.15 Med: 198.79 Max: 361.26
Current: 165.14
During the past 13 years, Jubilant Pharmova's highest Days Inventory was 361.26. The lowest was 134.15. And the median was 198.79.
BOM:530019's Days Inventory is ranked worse than 50.16% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs BOM:530019: 165.14
Jubilant Pharmova's Days Inventory
declined
from Mar. 2025 (164.57) to Mar. 2026 (157.54).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Jubilant Pharmova's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.58.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Jubilant Pharmova's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.54.
Jubilant Pharmova (BOM:530019) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Jubilant Pharmova's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Jubilant Pharmova's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Jubilant Pharmova Days Inventory Related Terms
Jubilant Pharmova Days Inventory Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Days Inventory distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a Days Inventory of 157.54 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Jubilant Pharmova and its competitors. This is 21% below median its historical median of 198.79. Over the past decade, Jubilant Pharmova's Days Inventory has ranged from 134.15 to 361.26. According to the industry distribution chart, Jubilant Pharmova ranks #463 out of 923 companies in the Drug Manufacturers industry, placing it in the top 50.2%.
Is Jubilant Pharmova's Days Inventory too high?
Jubilant Pharmova's current Days Inventory of 157.54 is 21% below median its 10-year median of 198.79. Over the past 10 years, this metric has ranged from a low of 134.15 to a high of 361.26. The Drug Manufacturers industry median Days Inventory is 164.87. Jubilant Pharmova's value of 157.54 is 4.4% below this industry median. Based on the distribution chart, Jubilant Pharmova ranks #463 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jubilant Pharmova has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #463 out of 923 companies for Days Inventory. This places Jubilant Pharmova in the lower half of its industry. The industry median Days Inventory is 164.87. Jubilant Pharmova's value of 157.54 is 4.4% below this benchmark. Historically, Jubilant Pharmova's own Days Inventory has ranged from 134.15 to 361.26 over the past decade. While the company's 10-year median is 198.79 vs. the industry median of 164.87, Jubilant Pharmova has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Days Inventory of 157.54 is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Days Inventory is 157.54, which is 21% below median its own 10-year median of 198.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,069.41, compared to a current price of ₹934.80 — trading 12.6% below its estimated fair value. The current Days Inventory is 157.54, which is 21% below median its 10-year median of 198.79 and 4.4% below the Drug Manufacturers industry median of 164.87. Jubilant Pharmova's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Days Inventory is 157.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹934.80 is trading 12.6% below its estimated GF Value™ of ₹1,069.41.
GuruFocus considers Jubilant Pharmova to be Modestly Undervalued.
Key valuation signals for BOM:530019:
Days Inventory: 157.54 (21% below median its 10-year median of 198.79)
GF Value™: ₹1,069.41 vs. price of ₹934.80 (12.6% below fair value)
Industry Position: 4.4% below the Drug Manufacturers median (#463 of 923)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
70GF Score
Get the complete analysis for BOM:530019
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
